HDAC9 and ovarian carcinoma: Since class I HDAC isoforms are expressed at significantly higher levels in ovarian cancer compared to normal ovarian tissue [24], and various HDAC inhibitors can prevent both in vitro and in vivo growth of ovarian cancer cells [25, 26], we investigated the in vivo efficacy of ST7612AA1 also in two ovarian carcinoma models.